Health Care & Life Sciences » Pharmaceuticals | Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB | Balance Sheet

Fiscal year is January-December. All values SEK Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
445
519
904
786
1,478
2,999
Total Accounts Receivable
515
594
584
1,130
1,523
2,165
Inventories
726
764
776
870
1,053
1,284
Other Current Assets
44
58
52
125
102
154
Total Current Assets
1,730
1,935
2,316
2,911
4,157
6,602
Net Property, Plant & Equipment
126
115
113
121
134
136
Total Investments and Advances
-
3
2
2
35
55
Intangible Assets
4,637
4,247
5,787
6,806
6,445
10,159
Other Assets
2
-
-
-
-
-
Total Assets
6,519
6,608
8,532
10,063
10,975
17,183
ST Debt & Current Portion LT Debt
-
2
20
-
-
Accounts Payable
239
236
183
280
358
Income Tax Payable
7
11
12
16
226
Other Current Liabilities
402
498
1,105
1,462
1,781
Total Current Liabilities
647
747
1,320
1,758
2,365
Long-Term Debt
791
816
800
502
5
Provision for Risks & Charges
9
13
42
44
98
Deferred Taxes
273
202
216
362
536
Other Liabilities
5
-
1,179
1,809
1,067
Total Liabilities
1,750
2,085
3,872
4,698
4,275
Common Equity (Total)
4,769
4,523
4,660
5,365
6,701
Total Shareholders' Equity
4,769
4,523
4,660
5,365
6,701
Total Equity
4,769
4,523
4,660
5,365
6,701
Liabilities & Shareholders' Equity
6,519
6,608
8,532
10,063
10,975

About Swedish Orphan Biovitrum AB

View Profile
Address
Tomtebodavägen 23A
Solna AB 112 76
Sweden
Employees -
Website http://www.sobi.com
Updated 07/08/2019
Swedish Orphan Biovitrum AB engages as a biopharmaceutical company. It provides therapies and services for patients with rare diseases. The firm's core products include Kineret within the inflammation therapeutic area; and Orfadin, Ammonaps, and Ammonul within the genetics and metabolic therapeutic area.